MX2021008205A - Constructos dirigidos a labyrinthin o una porcion del mismo y sus usos. - Google Patents
Constructos dirigidos a labyrinthin o una porcion del mismo y sus usos.Info
- Publication number
- MX2021008205A MX2021008205A MX2021008205A MX2021008205A MX2021008205A MX 2021008205 A MX2021008205 A MX 2021008205A MX 2021008205 A MX2021008205 A MX 2021008205A MX 2021008205 A MX2021008205 A MX 2021008205A MX 2021008205 A MX2021008205 A MX 2021008205A
- Authority
- MX
- Mexico
- Prior art keywords
- labyrinthin
- constructs targeting
- constructs
- targeting
- compositions
- Prior art date
Links
- 230000008685 targeting Effects 0.000 title 1
- 239000012636 effector Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Urology & Nephrology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
Abstract
Se proporcionan constructos que comprenden una porción de anticuerpo que se une específicamente a Labyrinthin o una porción del mismo y un dominio efector. También se proporcionan métodos para hacer y utilizar estos constructos y composiciones de los mismos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962789871P | 2019-01-08 | 2019-01-08 | |
PCT/US2020/012613 WO2020146413A1 (en) | 2019-01-08 | 2020-01-07 | Constructs targeting labyrinthin or a portion thereof and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021008205A true MX2021008205A (es) | 2021-11-12 |
Family
ID=71520309
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021008205A MX2021008205A (es) | 2019-01-08 | 2020-01-07 | Constructos dirigidos a labyrinthin o una porcion del mismo y sus usos. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220089719A1 (es) |
EP (1) | EP3908612A4 (es) |
JP (1) | JP2022517329A (es) |
KR (1) | KR20210137997A (es) |
CN (1) | CN113993892A (es) |
AU (1) | AU2020206329A1 (es) |
CA (1) | CA3126063A1 (es) |
IL (1) | IL284638A (es) |
MX (1) | MX2021008205A (es) |
TW (1) | TW202043270A (es) |
WO (1) | WO2020146413A1 (es) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6166176A (en) * | 1998-03-17 | 2000-12-26 | Immvarx, Inc. | Cancer marker protein and peptides thereof |
AU2005277547B2 (en) * | 2004-08-16 | 2011-08-25 | Immune Disease Institute, Inc. | Method of delivering RNA interference and uses thereof |
WO2011116014A2 (en) * | 2010-03-15 | 2011-09-22 | Mission Therapeutics, Inc. | Humanized antibodies to labyrinthin and uses thereof |
CN114478791A (zh) * | 2015-04-03 | 2022-05-13 | 优瑞科生物技术公司 | 靶向afp肽/mhc复合体的构建体及其用途 |
WO2019217913A1 (en) * | 2018-05-10 | 2019-11-14 | Sensei Biotherapeutics, Inc. | Aspartate beta-hydroxylase chimeric antigen receptors and uses thereof |
-
2020
- 2020-01-07 CN CN202080017505.2A patent/CN113993892A/zh active Pending
- 2020-01-07 WO PCT/US2020/012613 patent/WO2020146413A1/en unknown
- 2020-01-07 JP JP2021539522A patent/JP2022517329A/ja active Pending
- 2020-01-07 US US17/309,955 patent/US20220089719A1/en active Pending
- 2020-01-07 KR KR1020217025039A patent/KR20210137997A/ko unknown
- 2020-01-07 CA CA3126063A patent/CA3126063A1/en active Pending
- 2020-01-07 EP EP20738867.9A patent/EP3908612A4/en active Pending
- 2020-01-07 MX MX2021008205A patent/MX2021008205A/es unknown
- 2020-01-07 AU AU2020206329A patent/AU2020206329A1/en active Pending
- 2020-01-08 TW TW109100669A patent/TW202043270A/zh unknown
-
2021
- 2021-07-06 IL IL284638A patent/IL284638A/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20220089719A1 (en) | 2022-03-24 |
WO2020146413A1 (en) | 2020-07-16 |
EP3908612A4 (en) | 2023-01-18 |
IL284638A (en) | 2021-08-31 |
JP2022517329A (ja) | 2022-03-08 |
EP3908612A1 (en) | 2021-11-17 |
AU2020206329A1 (en) | 2021-08-05 |
CA3126063A1 (en) | 2020-07-16 |
KR20210137997A (ko) | 2021-11-18 |
CN113993892A (zh) | 2022-01-28 |
TW202043270A (zh) | 2020-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017502390A1 (en) | Constructs targeting ny-eso-1 peptide/mhc complexes and uses thereof | |
MX2021014441A (es) | Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos. | |
MX2017012352A (es) | Construccion dirigida a complejos de peptido de alfa-fetoproteina/complejo principal de histocompatibilidad (afp/cph) y usos de los mismos. | |
EP4218802A3 (en) | Conjugates for targeted cell surface editing | |
MX2017014056A (es) | Construcciones dirigidas a complejos de peptido e7 del subtipo 16 del virus de papiloma humano (hpv16-e7)/complejo principal de histocompatibilidad (mhc) y sus usos. | |
WO2018234793A3 (en) | Antibodies | |
PH12021550337A1 (en) | Anti-gdf15 antibodies, compositions and methods of use | |
MX2021003435A (es) | Moleculas inmunomoduladoras localizadas en el colageno y metodos de las mismas. | |
WO2019224716A3 (en) | Antibodies specific for gucy2c and uses thereof | |
JO3118B1 (ar) | تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة | |
AU2015370918A8 (en) | Binding protein drug conjugates comprising anthracycline derivatives | |
AR080513A1 (es) | Moleculas de union cd37 y sus inmunoconjugados | |
MX2022010515A (es) | Conjugacion mediada por transglutaminasa. | |
EP3790591A4 (en) | COMPOSITIONS AND METHODS RELATED TO ANTI-CD19 ANTIBODY-DRUG CONJUGATES | |
MX2020010227A (es) | Construcciones dirigidas a cd22 y usos de las mismas. | |
PH12020551716A1 (en) | Anti-ror antibody constructs | |
MX2017005199A (es) | Conjugados y reactivos de conjugacion. | |
MX2021008592A (es) | Composiciones de trem y usos de las mismas. | |
MX2017003472A (es) | Inmunoconjugados que comprenden anticuerpos anti-her2. | |
BR112017019617A2 (pt) | Anticorpo, composto conjugado anticorpo- fármaco anti-cd48, composição de conjugado anticorpo-fármaco, métodos para tratar um paciente com um câncer que expressa cd48, para produzir um anticorpo anti-cd48 e para produzir um conjugado anticorpo-fármaco anti-cd48, ácido nucléico isolado, vetor isolado, e, célula hospedeira isolada | |
MX2021009138A (es) | Anticuerpos anti-cd228 y conjugados de anticuerpo-farmaco. | |
EA202192405A1 (ru) | Составы антител против il-36r | |
BR112021024956A2 (pt) | Anticorpos multiespecíficos de cadeia pesada que se ligam a cd22 e cd3 | |
PH12018500159A1 (en) | Constructs targeting psa peptide/mhc complexes and uses thereof | |
BR112021016056A2 (pt) | Anticorpos de claudina 6 e usos dos mesmos |